MoonLake Immunotherapeutics (NASDAQ:MLTX) stock is trading higher on Monday after the company reported encouraging 52-week results from its Phase 3 VELA-1 and VELA-2 studies evaluating sonelokimab (SLK) for moderate-to-severe hidradenitis suppurativa (HS).
The data released on Sunday showed sustained improvements in disease control, quality of life, and pain reduction.
The clinical-stage biotech also said it remains on track to submit a Biologics License Application (BLA) for SLK to the FDA by the end of September 2026.
In March, MoonLake announced that 62% of patients treated with sonelokimab achieved a HiSCR75 response by Week 40, setting a new standard for long-term lesion control in HS.
Strong One-Year Efficacy Across MoonLake Phase 3 Program
